Show simple item record

dc.contributor.authorNunes-Xavier, Caroline Elisabeth
dc.contributor.authorEmaldi, Maite
dc.contributor.authorGuldvik, Ingrid Jenny
dc.contributor.authorRamberg, Håkon
dc.contributor.authorTasken, Kristin Austlid
dc.contributor.authorMælandsmo, Gunhild Mari
dc.contributor.authorFodstad, Øystein
dc.contributor.authorLlarena, Roberto
dc.contributor.authorPulido, Rafael
dc.contributor.authorLopez, José I.
dc.date.accessioned2023-02-23T11:22:39Z
dc.date.available2023-02-23T11:22:39Z
dc.date.issued2022-11-24
dc.description.abstractProstate cancer diagnosis and early stratification is an important aspect to avoid undertreatment of high-risk prostate cancer patients. Major Vault Protein (MVP) has been proposed as a prognostic biomarker in prostate cancer. PTEN and the immune checkpoint protein B7-H3 interact with MVP and are important in prostate cancer progression and therapy response. We evaluated the expression of MVP by immunohistochemistry of tissue microarray samples from a retrospective cohort consisting of 119 prostate cancer patients. We correlated the protein expression of MVP with clinicopathological characteristics, and protein expression of androgen receptor (AR), PTEN, immune checkpoint proteins B7-H3 and PD-L1. We found MVP to be expressed in 53 % of prostate tumors, and correlated positively with biochemical recurrence (ρ = 0.211/p = 0.021). Furthermore, we found positive correlation of MVP expression with expression of AR (ρ = 0.244/p = 0.009) and the immune checkpoint protein B7-H3 (ρ = 0.200/p = 0.029), but not with PD-L1 (ρ = 0.152/p = 0.117) or PTEN expression (ρ = − 0.034/p = 0.721). Our findings support the notion that expression of MVP is associated with poor prognosis in prostate cancer. The correlation between MVP and immune checkpoint protein B7-H3 in prostate cancer suggests a role for MVP in immunoregulation and drug resistance.en_US
dc.identifier.citationNunes-Xavier CE, Emaldi M, Guldvik IJ, Ramberg H, Tasken KA, Mælandsmo GM, Fodstad Ø, Llarena R, Pulido R, Lopez JI. Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer. Pathology, Research and Practice. 2022en_US
dc.identifier.cristinIDFRIDAID 2127749
dc.identifier.doi10.1016/j.prp.2022.154243
dc.identifier.issn0344-0338
dc.identifier.issn1618-0631
dc.identifier.urihttps://hdl.handle.net/10037/28603
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalPathology, Research and Practice
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)en_US
dc.titleCorrelation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate canceren_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)